Fusion Pharmaceuticals Stock Beta
| FUSNDelisted Stock | USD 3.75 0.33 8.09% |
Fusion Pharmaceuticals fundamentals help investors to digest information that contributes to Fusion Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Fusion Stock. The fundamental analysis module provides a way to measure Fusion Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fusion Pharmaceuticals stock.
Fusion |
Fusion Pharmaceuticals Company Beta Analysis
Fusion Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Fusion Pharmaceuticals Beta | -0.69 |
Most of Fusion Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fusion Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Fusion Pharmaceuticals has a Beta of -0.689. This is 180.12% lower than that of the Biotechnology sector and 149.57% lower than that of the Health Care industry. The beta for all United States stocks is notably higher than that of the company.
Fusion Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fusion Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fusion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Fusion Pharmaceuticals by comparing valuation metrics of similar companies.Fusion Pharmaceuticals is currently under evaluation in beta category among its peers.
As returns on the market increase, returns on owning Fusion Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Fusion Pharmaceuticals is likely to outperform the market.
Fusion Fundamentals
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (54.04) % | |||
| Current Valuation | 1.69 B | |||
| Shares Outstanding | 85.06 M | |||
| Shares Owned By Insiders | 0.46 % | |||
| Shares Owned By Institutions | 86.80 % | |||
| Number Of Shares Shorted | 3.06 M | |||
| Price To Book | 8.13 X | |||
| Price To Sales | 874.50 X | |||
| Revenue | 2.07 M | |||
| Gross Profit | (57.43 M) | |||
| EBITDA | (97.89 M) | |||
| Net Income | (94.9 M) | |||
| Cash And Equivalents | 198.42 M | |||
| Cash Per Share | 4.57 X | |||
| Total Debt | 50.33 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 17.89 X | |||
| Book Value Per Share | 2.85 X | |||
| Cash Flow From Operations | (81.8 M) | |||
| Short Ratio | 6.22 X | |||
| Earnings Per Share | (1.40) X | |||
| Target Price | 21.14 | |||
| Number Of Employees | 101 | |||
| Beta | -0.69 | |||
| Market Capitalization | 1.83 B | |||
| Total Asset | 285.84 M | |||
| Retained Earnings | (376.76 M) | |||
| Working Capital | 227.18 M | |||
| Net Asset | 285.84 M |
About Fusion Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fusion Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fusion Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fusion Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Fusion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fusion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fusion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Fusion Stock
| 0.39 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
| 0.38 | EC | Ecopetrol SA ADR Sell-off Trend | PairCorr |
| 0.34 | PG | Procter Gamble Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Fusion Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fusion Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fusion Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fusion Pharmaceuticals to buy it.
The correlation of Fusion Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fusion Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fusion Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fusion Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Fusion Stock
If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |